These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 9408138)
1. In vivo quantification of citrate concentration and water T2 relaxation time of the pathologic prostate gland using 1H MRS and MRI. Liney GP; Turnbull LW; Lowry M; Turnbull LS; Knowles AJ; Horsman A Magn Reson Imaging; 1997; 15(10):1177-86. PubMed ID: 9408138 [TBL] [Abstract][Full Text] [Related]
2. Proton MR T2 maps correlate with the citrate concentration in the prostate. Liney GP; Lowry M; Turnbull LW; Manton DJ; Knowles AJ; Blackband SJ; Horsman A NMR Biomed; 1996 Apr; 9(2):59-64. PubMed ID: 8887369 [TBL] [Abstract][Full Text] [Related]
3. MR spectroscopy of the prostate at 3T: measurements of relaxation times and quantification of prostate metabolites using water as an internal reference. Weis J; Ortiz-Nieto F; Ahlström H Magn Reson Med Sci; 2013 Dec; 12(4):289-96. PubMed ID: 24172792 [TBL] [Abstract][Full Text] [Related]
4. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Kurhanewicz J; Vigneron DB; Nelson SJ; Hricak H; MacDonald JM; Konety B; Narayan P Urology; 1995 Mar; 45(3):459-66. PubMed ID: 7533458 [TBL] [Abstract][Full Text] [Related]
5. In vitro high resolution 1H-spectroscopy of the human prostate: benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma. Schiebler ML; Miyamoto KK; White M; Maygarden SJ; Mohler JL Magn Reson Med; 1993 Mar; 29(3):285-91. PubMed ID: 7680746 [TBL] [Abstract][Full Text] [Related]
6. Proton magnetic resonance spectroscopy with a body coil in the diagnosis of carcinoma prostate. Kumar R; Kumar M; Jagannathan NR; Gupta NP; Hemal AK Urol Res; 2004 Feb; 32(1):36-40. PubMed ID: 14534764 [TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of proton magnetic resonance spectroscopy (1H-MRS) in the diagnosis of localized prostate cancer. Saito K; Kaminaga T; Muto S; Ide H; Nishio K; Kamiyama Y; Okada H; Terado Y; Furui S; Horie S Anticancer Res; 2008; 28(3B):1899-904. PubMed ID: 18630478 [TBL] [Abstract][Full Text] [Related]
8. A decrease in 1H nuclear magnetic resonance spectroscopically determined citrate in human seminal fluid accompanies the development of prostate adenocarcinoma. Averna TA; Kline EE; Smith AY; Sillerud LO J Urol; 2005 Feb; 173(2):433-8. PubMed ID: 15643195 [TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance spectroscopy in prostate disease: diagnostic possibilities and future developments. Narayan P; Kurhanewicz J Prostate Suppl; 1992; 4():43-50. PubMed ID: 1374177 [TBL] [Abstract][Full Text] [Related]
11. In vivo differential diagnosis of prostate cancer and benign prostatic hyperplasia: localized proton magnetic resonance spectroscopy using external-body surface coil. Kim JK; Kim DY; Lee YH; Sung NK; Chung DS; Kim OD; Kim KB Magn Reson Imaging; 1998 Dec; 16(10):1281-8. PubMed ID: 9858286 [TBL] [Abstract][Full Text] [Related]
13. MR spectroscopy as a reliable diagnostic tool for localization of prostate cancer. Hasumi M; Suzuki K; Oya N; Ito K; Kurokawa K; Fukabori Y; Yamanaka H Anticancer Res; 2002; 22(2B):1205-8. PubMed ID: 12168926 [TBL] [Abstract][Full Text] [Related]
14. Quantification of metabolite concentrations in benign and malignant prostate tissues using 3D proton MR spectroscopic imaging. Weis J; von Below C; Tolf A; Ortiz-Nieto F; Wassberg C; Häggman M; Ladjevardi S; Ahlström H J Magn Reson Imaging; 2017 Apr; 45(4):1232-1240. PubMed ID: 27556571 [TBL] [Abstract][Full Text] [Related]
15. Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings. Aydin H; Kizilgöz V; Tatar IG; Damar C; Ugan AR; Paker I; Hekimoğlu B J Comput Assist Tomogr; 2012; 36(1):30-45. PubMed ID: 22261768 [TBL] [Abstract][Full Text] [Related]
16. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Kurhanewicz J; Vigneron DB; Hricak H; Narayan P; Carroll P; Nelson SJ Radiology; 1996 Mar; 198(3):795-805. PubMed ID: 8628874 [TBL] [Abstract][Full Text] [Related]
17. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology. García-Segura JM; Sánchez-Chapado M; Ibarburen C; Viaño J; Angulo JC; González J; Rodríguez-Vallejo JM Magn Reson Imaging; 1999 Jun; 17(5):755-65. PubMed ID: 10372529 [TBL] [Abstract][Full Text] [Related]
18. In vitro proton spectroscopy of normal and abnormal prostate. Yacoe ME; Sommer G; Peehl D Magn Reson Med; 1991 Jun; 19(2):429-38. PubMed ID: 1715505 [TBL] [Abstract][Full Text] [Related]
19. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Kurhanewicz J; Vigneron DB; Hricak H; Parivar F; Nelson SJ; Shinohara K; Carroll PR Radiology; 1996 Aug; 200(2):489-96. PubMed ID: 8685346 [TBL] [Abstract][Full Text] [Related]
20. Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study. Kurhanewicz J; Dahiya R; Macdonald JM; Chang LH; James TL; Narayan P Magn Reson Med; 1993 Feb; 29(2):149-57. PubMed ID: 8429778 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]